Pretransplant Midodrine Use

A Newly Identified Risk Marker for Complications after Kidney Transplantation

Tarek Alhamad, Daniel Brennan, Zaid Brifkani, Huiling Xiao, Mark A. Schnitzler, Vikas R. Dharnidharka, David Axelrod, Dorry Segev, Krista L. Lentine

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Midodrine is prescribed to prevent symptomatic hypotension and decrease complications associated with hypotension during dialysis. We hypothesized that midodrine use before kidney transplantation may be a novel marker for posttransplant risk. METHODS: We analyzed integrated national US transplant registry, pharmacy records, and Medicare claims data for 16 308 kidney transplant recipients transplanted 2006 to 2008, of whom 308 (1.9%) had filled midodrine prescriptions in the year before transplantation. Delayed graft function (DGF), graft failure, and patient death were ascertained from the registry. Posttransplant cardiovascular complications were identified using diagnosis codes on Medicare billing claims. Adjusted associations of pretransplant midodrine use with complications at 3 and 12 months posttransplant were quantified by multivariate Cox or logistic regression, including propensity for midodrine exposure. RESULTS: At 3 months, patients who used midodrine pretransplant had significantly (P <0.05) higher rates of DGF, 32% versus 19%; hypotension, 14% versus 4%; acute myocardial infarction, 4% versus 2%; cardiac arrest, 2% versus 0.9%, graft failure, 5% versus 2%; and death, 4% versus 1% than nonusers. After multivariate adjustment including recipient and donor factors, as well as for the propensity of midodrine exposure, pretransplant midodrine use was independently associated with risks of DGF (adjusted odds ratio, 1.78; 95% confidence interval [CI], 1.36-2.32), and 3 month death-censored graft failure (adjusted hazard ratio, 2.0; 95% CI, 1.18-3.39), and death (adjusted hazard ratio, 3.49; 95% CI, 1.95-6.24). Patterns were similar at 12 months. CONCLUSIONS: Although associations may in part reflect underlying conditions, the need for midodrine before kidney transplantation is a risk marker for complications including DGF, graft failure, and death.

Original languageEnglish (US)
JournalTransplantation
DOIs
StateAccepted/In press - Mar 4 2016

Fingerprint

Midodrine
Kidney Transplantation
Delayed Graft Function
Transplants
Hypotension
Confidence Intervals
Medicare
Registries
Heart Arrest
Prescriptions
Dialysis
Transplantation
Logistic Models
Odds Ratio
Myocardial Infarction
Tissue Donors

ASJC Scopus subject areas

  • Transplantation

Cite this

Alhamad, T., Brennan, D., Brifkani, Z., Xiao, H., Schnitzler, M. A., Dharnidharka, V. R., ... Lentine, K. L. (Accepted/In press). Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications after Kidney Transplantation. Transplantation. https://doi.org/10.1097/TP.0000000000001113

Pretransplant Midodrine Use : A Newly Identified Risk Marker for Complications after Kidney Transplantation. / Alhamad, Tarek; Brennan, Daniel; Brifkani, Zaid; Xiao, Huiling; Schnitzler, Mark A.; Dharnidharka, Vikas R.; Axelrod, David; Segev, Dorry; Lentine, Krista L.

In: Transplantation, 04.03.2016.

Research output: Contribution to journalArticle

Alhamad, Tarek ; Brennan, Daniel ; Brifkani, Zaid ; Xiao, Huiling ; Schnitzler, Mark A. ; Dharnidharka, Vikas R. ; Axelrod, David ; Segev, Dorry ; Lentine, Krista L. / Pretransplant Midodrine Use : A Newly Identified Risk Marker for Complications after Kidney Transplantation. In: Transplantation. 2016.
@article{8cda5fb90f31410e985dd1d1081bb9f4,
title = "Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications after Kidney Transplantation",
abstract = "BACKGROUND: Midodrine is prescribed to prevent symptomatic hypotension and decrease complications associated with hypotension during dialysis. We hypothesized that midodrine use before kidney transplantation may be a novel marker for posttransplant risk. METHODS: We analyzed integrated national US transplant registry, pharmacy records, and Medicare claims data for 16 308 kidney transplant recipients transplanted 2006 to 2008, of whom 308 (1.9{\%}) had filled midodrine prescriptions in the year before transplantation. Delayed graft function (DGF), graft failure, and patient death were ascertained from the registry. Posttransplant cardiovascular complications were identified using diagnosis codes on Medicare billing claims. Adjusted associations of pretransplant midodrine use with complications at 3 and 12 months posttransplant were quantified by multivariate Cox or logistic regression, including propensity for midodrine exposure. RESULTS: At 3 months, patients who used midodrine pretransplant had significantly (P <0.05) higher rates of DGF, 32{\%} versus 19{\%}; hypotension, 14{\%} versus 4{\%}; acute myocardial infarction, 4{\%} versus 2{\%}; cardiac arrest, 2{\%} versus 0.9{\%}, graft failure, 5{\%} versus 2{\%}; and death, 4{\%} versus 1{\%} than nonusers. After multivariate adjustment including recipient and donor factors, as well as for the propensity of midodrine exposure, pretransplant midodrine use was independently associated with risks of DGF (adjusted odds ratio, 1.78; 95{\%} confidence interval [CI], 1.36-2.32), and 3 month death-censored graft failure (adjusted hazard ratio, 2.0; 95{\%} CI, 1.18-3.39), and death (adjusted hazard ratio, 3.49; 95{\%} CI, 1.95-6.24). Patterns were similar at 12 months. CONCLUSIONS: Although associations may in part reflect underlying conditions, the need for midodrine before kidney transplantation is a risk marker for complications including DGF, graft failure, and death.",
author = "Tarek Alhamad and Daniel Brennan and Zaid Brifkani and Huiling Xiao and Schnitzler, {Mark A.} and Dharnidharka, {Vikas R.} and David Axelrod and Dorry Segev and Lentine, {Krista L.}",
year = "2016",
month = "3",
day = "4",
doi = "10.1097/TP.0000000000001113",
language = "English (US)",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Pretransplant Midodrine Use

T2 - A Newly Identified Risk Marker for Complications after Kidney Transplantation

AU - Alhamad, Tarek

AU - Brennan, Daniel

AU - Brifkani, Zaid

AU - Xiao, Huiling

AU - Schnitzler, Mark A.

AU - Dharnidharka, Vikas R.

AU - Axelrod, David

AU - Segev, Dorry

AU - Lentine, Krista L.

PY - 2016/3/4

Y1 - 2016/3/4

N2 - BACKGROUND: Midodrine is prescribed to prevent symptomatic hypotension and decrease complications associated with hypotension during dialysis. We hypothesized that midodrine use before kidney transplantation may be a novel marker for posttransplant risk. METHODS: We analyzed integrated national US transplant registry, pharmacy records, and Medicare claims data for 16 308 kidney transplant recipients transplanted 2006 to 2008, of whom 308 (1.9%) had filled midodrine prescriptions in the year before transplantation. Delayed graft function (DGF), graft failure, and patient death were ascertained from the registry. Posttransplant cardiovascular complications were identified using diagnosis codes on Medicare billing claims. Adjusted associations of pretransplant midodrine use with complications at 3 and 12 months posttransplant were quantified by multivariate Cox or logistic regression, including propensity for midodrine exposure. RESULTS: At 3 months, patients who used midodrine pretransplant had significantly (P <0.05) higher rates of DGF, 32% versus 19%; hypotension, 14% versus 4%; acute myocardial infarction, 4% versus 2%; cardiac arrest, 2% versus 0.9%, graft failure, 5% versus 2%; and death, 4% versus 1% than nonusers. After multivariate adjustment including recipient and donor factors, as well as for the propensity of midodrine exposure, pretransplant midodrine use was independently associated with risks of DGF (adjusted odds ratio, 1.78; 95% confidence interval [CI], 1.36-2.32), and 3 month death-censored graft failure (adjusted hazard ratio, 2.0; 95% CI, 1.18-3.39), and death (adjusted hazard ratio, 3.49; 95% CI, 1.95-6.24). Patterns were similar at 12 months. CONCLUSIONS: Although associations may in part reflect underlying conditions, the need for midodrine before kidney transplantation is a risk marker for complications including DGF, graft failure, and death.

AB - BACKGROUND: Midodrine is prescribed to prevent symptomatic hypotension and decrease complications associated with hypotension during dialysis. We hypothesized that midodrine use before kidney transplantation may be a novel marker for posttransplant risk. METHODS: We analyzed integrated national US transplant registry, pharmacy records, and Medicare claims data for 16 308 kidney transplant recipients transplanted 2006 to 2008, of whom 308 (1.9%) had filled midodrine prescriptions in the year before transplantation. Delayed graft function (DGF), graft failure, and patient death were ascertained from the registry. Posttransplant cardiovascular complications were identified using diagnosis codes on Medicare billing claims. Adjusted associations of pretransplant midodrine use with complications at 3 and 12 months posttransplant were quantified by multivariate Cox or logistic regression, including propensity for midodrine exposure. RESULTS: At 3 months, patients who used midodrine pretransplant had significantly (P <0.05) higher rates of DGF, 32% versus 19%; hypotension, 14% versus 4%; acute myocardial infarction, 4% versus 2%; cardiac arrest, 2% versus 0.9%, graft failure, 5% versus 2%; and death, 4% versus 1% than nonusers. After multivariate adjustment including recipient and donor factors, as well as for the propensity of midodrine exposure, pretransplant midodrine use was independently associated with risks of DGF (adjusted odds ratio, 1.78; 95% confidence interval [CI], 1.36-2.32), and 3 month death-censored graft failure (adjusted hazard ratio, 2.0; 95% CI, 1.18-3.39), and death (adjusted hazard ratio, 3.49; 95% CI, 1.95-6.24). Patterns were similar at 12 months. CONCLUSIONS: Although associations may in part reflect underlying conditions, the need for midodrine before kidney transplantation is a risk marker for complications including DGF, graft failure, and death.

UR - http://www.scopus.com/inward/record.url?scp=84960158299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960158299&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000001113

DO - 10.1097/TP.0000000000001113

M3 - Article

JO - Transplantation

JF - Transplantation

SN - 0041-1337

ER -